Skip to main content
Top
Published in: BMC Urology 1/2011

Open Access 01-12-2011 | Research article

ROS generation via NOX4 and its utility in the cytological diagnosis of urothelial carcinoma of the urinary bladder

Authors: Keiji Shimada, Tomomi Fujii, Satoshi Anai, Kiyohide Fujimoto, Noboru Konishi

Published in: BMC Urology | Issue 1/2011

Login to get access

Abstract

Background

Reactive oxygen species (ROS) production via NADPH oxidase (NOX) contributes to various types of cancer progression. In the present research, we examined the pathobiological role of NADPH oxidase (NOX)4-mediated generation of reactive oxygen species (ROS) in urothelial carcinoma (UC) of the urinary bladder, and demonstrated the utility of ROS labeling in urine cytology.

Methods

NOX4 gene was silenced in vivo and in vitro by NOX4 siRNA transfection with or without atlocollagen. Cell cycle and measurement of ROS were analyzed by flowcytometry. Orthotopic implantation animal model was used in vivo experiment. NOX4 expression in urothelial carcinoma cells was observed by immunohistochemical analysis using surgical specimens of human bladder cancer. Urine cytology was performed after treatment with ROS detection reagents in addition to Papanicolaou staining.

Results

NOX4 was overexpressed in several UC cell lines and the NOX inhibitor, diphenylene iodonium reduced intracellular ROS and induced p16-dependent cell cycle arrest at the G1 phase. Moreover, silencing of NOX4 by siRNA significantly reduced cancer cell growth in vivo as assessed in an orthotopic mouse model. Immunohistochemistry demonstrated high expression of NOX4 in low grade/non-invasive and high grade/invasive UC including precancerous lesions such as dysplasia but not in normal urothelium. Then, we assessed the usefulness of cytological analysis of ROS producing cells in urine (ROS-C). Urine samples obtained from UC cases and normal controls were treated with fluorescent reagents labeling the hydrogen peroxide/superoxide anion and cytological atypia of ROS positive cells were analyzed. As a result, the sensitivity for detection of low grade, non-invasive UC was greatly increased (35% in conventional cytology (C-C) vs. 75% in ROS-C), and the specificity was 95%. Through ROS-C, we observed robust improvement in the accuracy of follow-up urine cytology for cases with previously diagnosed UC, especially in those with low grade/non-invasive cancer recurrence (0% in C-C vs. 64% in ROS-C).

Conclusions

This is the first report demonstrating that ROS generation through NOX4 contributes to an early step of urothelial carcinogenesis and cancer cell survival. In addition, cytology using ROS labeling could be a useful diagnostic tool in human bladder cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Babjuk M, Oosterlinck W, Sylvester R, et al: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. European urology. 2008, 54 (2): 303-14. 10.1016/j.eururo.2008.04.051.CrossRefPubMed Babjuk M, Oosterlinck W, Sylvester R, et al: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. European urology. 2008, 54 (2): 303-14. 10.1016/j.eururo.2008.04.051.CrossRefPubMed
2.
go back to reference Kakizoe T: Development and progression of urothelial carcinoma. Cancer science. 2006, 97 (9): 821-8. 10.1111/j.1349-7006.2006.00264.x.CrossRefPubMed Kakizoe T: Development and progression of urothelial carcinoma. Cancer science. 2006, 97 (9): 821-8. 10.1111/j.1349-7006.2006.00264.x.CrossRefPubMed
3.
go back to reference Proctor I, Stoeber K, Williams GH: Biomarkers in bladder cancer. Histopathology. 57 (1): 1-13. Proctor I, Stoeber K, Williams GH: Biomarkers in bladder cancer. Histopathology. 57 (1): 1-13.
4.
go back to reference Amin MB: Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol. 2009, 22 (Suppl 2): S96-S118.CrossRefPubMed Amin MB: Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol. 2009, 22 (Suppl 2): S96-S118.CrossRefPubMed
5.
go back to reference Black PC, Brown GA, Dinney CP: The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urologic oncology. 2009, 27 (1): 3-7.CrossRefPubMed Black PC, Brown GA, Dinney CP: The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urologic oncology. 2009, 27 (1): 3-7.CrossRefPubMed
6.
go back to reference Nigwekar P, Amin MB: The many faces of urothelial carcinoma: an update with an emphasis on recently described variants. Advances in anatomic pathology. 2008, 15 (4): 218-33. 10.1097/PAP.0b013e31817d79b9.CrossRefPubMed Nigwekar P, Amin MB: The many faces of urothelial carcinoma: an update with an emphasis on recently described variants. Advances in anatomic pathology. 2008, 15 (4): 218-33. 10.1097/PAP.0b013e31817d79b9.CrossRefPubMed
7.
go back to reference Black PC, Brown GA, Dinney CP: Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol. 2006, 24 (35): 5528-35. 10.1200/JCO.2006.08.0895.CrossRefPubMed Black PC, Brown GA, Dinney CP: Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol. 2006, 24 (35): 5528-35. 10.1200/JCO.2006.08.0895.CrossRefPubMed
8.
go back to reference Budman LI, Kassouf W, Steinberg JR: Biomarkers for detection and surveillance of bladder cancer. Canadian Urological Association journal = Journal de l'Association des urologues du Canada. 2008, 2 (3): 212-21.PubMedPubMedCentral Budman LI, Kassouf W, Steinberg JR: Biomarkers for detection and surveillance of bladder cancer. Canadian Urological Association journal = Journal de l'Association des urologues du Canada. 2008, 2 (3): 212-21.PubMedPubMedCentral
9.
go back to reference Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T: Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science (New York, NY. 1995, 270 (5234): 296-9. 10.1126/science.270.5234.296.CrossRef Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T: Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science (New York, NY. 1995, 270 (5234): 296-9. 10.1126/science.270.5234.296.CrossRef
10.
go back to reference Shibanuma M, Arata S, Murata M, Nose K: Activation of DNA synthesis and expression of the JE gene by catalase in mouse osteoblastic cells: possible involvement of hydrogen peroxide in negative growth regulation. Experimental cell research. 1995, 218 (1): 132-6. 10.1006/excr.1995.1139.CrossRefPubMed Shibanuma M, Arata S, Murata M, Nose K: Activation of DNA synthesis and expression of the JE gene by catalase in mouse osteoblastic cells: possible involvement of hydrogen peroxide in negative growth regulation. Experimental cell research. 1995, 218 (1): 132-6. 10.1006/excr.1995.1139.CrossRefPubMed
11.
go back to reference Doudican NA, Song B, Shadel GS, Doetsch PW: Oxidative DNA damage causes mitochondrial genomic instability in Saccharomyces cerevisiae. Molecular and cellular biology. 2005, 25 (12): 5196-204. 10.1128/MCB.25.12.5196-5204.2005.CrossRefPubMedPubMedCentral Doudican NA, Song B, Shadel GS, Doetsch PW: Oxidative DNA damage causes mitochondrial genomic instability in Saccharomyces cerevisiae. Molecular and cellular biology. 2005, 25 (12): 5196-204. 10.1128/MCB.25.12.5196-5204.2005.CrossRefPubMedPubMedCentral
12.
go back to reference Irani K, Xia Y, Zweier JL, et al: Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science (New York, NY. 1997, 275 (5306): 1649-52. 10.1126/science.275.5306.1649.CrossRef Irani K, Xia Y, Zweier JL, et al: Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science (New York, NY. 1997, 275 (5306): 1649-52. 10.1126/science.275.5306.1649.CrossRef
13.
go back to reference Segal AW, Shatwell KP: The NADPH oxidase of phagocytic leukocytes. Annals of the New York Academy of Sciences. 1997, 832: 215-22. 10.1111/j.1749-6632.1997.tb46249.x.CrossRefPubMed Segal AW, Shatwell KP: The NADPH oxidase of phagocytic leukocytes. Annals of the New York Academy of Sciences. 1997, 832: 215-22. 10.1111/j.1749-6632.1997.tb46249.x.CrossRefPubMed
14.
go back to reference Shimada K, Nakamura M, Anai S, et al: A novel human AlkB homologue, ALKBH8, contributes to human bladder cancer progression. Cancer research. 2009, 69 (7): 3157-64. 10.1158/0008-5472.CAN-08-3530.CrossRefPubMed Shimada K, Nakamura M, Anai S, et al: A novel human AlkB homologue, ALKBH8, contributes to human bladder cancer progression. Cancer research. 2009, 69 (7): 3157-64. 10.1158/0008-5472.CAN-08-3530.CrossRefPubMed
15.
go back to reference Konishi N, Nakamura M, Kishi M, et al: Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas. The American journal of pathology. 2002, 160 (4): 1207-14. 10.1016/S0002-9440(10)62547-3.CrossRefPubMedPubMedCentral Konishi N, Nakamura M, Kishi M, et al: Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas. The American journal of pathology. 2002, 160 (4): 1207-14. 10.1016/S0002-9440(10)62547-3.CrossRefPubMedPubMedCentral
16.
go back to reference Shimada K, Nakamura M, Ishida E, et al: c-Jun NH2 terminal kinase activation and decreased expression of mitogen-activated protein kinase phosphatase-1 play important roles in invasion and angiogenesis of urothelial carcinomas. The American journal of pathology. 2007, 171 (3): 1003-12. 10.2353/ajpath.2007.070010.CrossRefPubMedPubMedCentral Shimada K, Nakamura M, Ishida E, et al: c-Jun NH2 terminal kinase activation and decreased expression of mitogen-activated protein kinase phosphatase-1 play important roles in invasion and angiogenesis of urothelial carcinomas. The American journal of pathology. 2007, 171 (3): 1003-12. 10.2353/ajpath.2007.070010.CrossRefPubMedPubMedCentral
17.
go back to reference Shimada K, Matsuyoshi S, Nakamura M, Ishida E, Konishi N: Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression. The Journal of pathology. 2005, 206 (4): 423-32. 10.1002/path.1791.CrossRefPubMed Shimada K, Matsuyoshi S, Nakamura M, Ishida E, Konishi N: Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression. The Journal of pathology. 2005, 206 (4): 423-32. 10.1002/path.1791.CrossRefPubMed
18.
go back to reference Shimada K, Nakamura M, De Velasco MA: Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma. Cancer science. 101 (1): 155-60. Shimada K, Nakamura M, De Velasco MA: Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma. Cancer science. 101 (1): 155-60.
19.
go back to reference Murata S, Iseki M, Kinjo M: Molecular and immunohistologic analyses cannot reliably solve diagnostic variation of flat intraepithelial lesions of the urinary bladder. American journal of clinical pathology. 134 (6): 862-72. Murata S, Iseki M, Kinjo M: Molecular and immunohistologic analyses cannot reliably solve diagnostic variation of flat intraepithelial lesions of the urinary bladder. American journal of clinical pathology. 134 (6): 862-72.
20.
go back to reference Mochizuki T, Furuta S, Mitsushita J, et al: Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells. Oncogene. 2006, 25 (26): 3699-707. 10.1038/sj.onc.1209406.CrossRefPubMed Mochizuki T, Furuta S, Mitsushita J, et al: Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells. Oncogene. 2006, 25 (26): 3699-707. 10.1038/sj.onc.1209406.CrossRefPubMed
21.
go back to reference McShane LM, Altman DG, Sauerbrei W: Identification of clinically useful cancer prognostic factors: what are we missing?. Journal of the National Cancer Institute. 2005, 97 (14): 1023-5. 10.1093/jnci/dji193.CrossRefPubMed McShane LM, Altman DG, Sauerbrei W: Identification of clinically useful cancer prognostic factors: what are we missing?. Journal of the National Cancer Institute. 2005, 97 (14): 1023-5. 10.1093/jnci/dji193.CrossRefPubMed
22.
go back to reference Ludwig JA, Weinstein JN: Biomarkers in cancer staging, prognosis and treatment selection. Nature reviews. 2005, 5 (11): 845-56. 10.1038/nrc1739.PubMed Ludwig JA, Weinstein JN: Biomarkers in cancer staging, prognosis and treatment selection. Nature reviews. 2005, 5 (11): 845-56. 10.1038/nrc1739.PubMed
23.
go back to reference Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A: Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. The Journal of urology. 1999, 162 (1): 53-7. 10.1097/00005392-199907000-00014.CrossRefPubMed Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A: Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. The Journal of urology. 1999, 162 (1): 53-7. 10.1097/00005392-199907000-00014.CrossRefPubMed
24.
go back to reference van Rhijn BW, van der Poel HG, van der Kwast TH: Urine markers for bladder cancer surveillance: a systematic review. European urology. 2005, 47 (6): 736-48. 10.1016/j.eururo.2005.03.014.CrossRefPubMed van Rhijn BW, van der Poel HG, van der Kwast TH: Urine markers for bladder cancer surveillance: a systematic review. European urology. 2005, 47 (6): 736-48. 10.1016/j.eururo.2005.03.014.CrossRefPubMed
25.
go back to reference Grossman HB, Soloway M, Messing E, et al: Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. Jama. 2006, 295 (3): 299-305. 10.1001/jama.295.3.299.CrossRefPubMed Grossman HB, Soloway M, Messing E, et al: Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. Jama. 2006, 295 (3): 299-305. 10.1001/jama.295.3.299.CrossRefPubMed
26.
go back to reference Shariat SF, Karam JA, Lotan Y, Karakiewizc PI: Critical evaluation of urinary markers for bladder cancer detection and monitoring. Reviews in urology. 2008, 10 (2): 120-35.PubMedPubMedCentral Shariat SF, Karam JA, Lotan Y, Karakiewizc PI: Critical evaluation of urinary markers for bladder cancer detection and monitoring. Reviews in urology. 2008, 10 (2): 120-35.PubMedPubMedCentral
27.
go back to reference Sarosdy MF, Schellhammer P, Bokinsky G, et al: Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. The Journal of urology. 2002, 168 (5): 1950-4. 10.1016/S0022-5347(05)64270-X.CrossRefPubMed Sarosdy MF, Schellhammer P, Bokinsky G, et al: Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. The Journal of urology. 2002, 168 (5): 1950-4. 10.1016/S0022-5347(05)64270-X.CrossRefPubMed
28.
go back to reference Halling KC, King W, Sokolova IA, et al: A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. The Journal of urology. 2002, 167 (5): 2001-6. 10.1016/S0022-5347(05)65072-0.CrossRefPubMed Halling KC, King W, Sokolova IA, et al: A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. The Journal of urology. 2002, 167 (5): 2001-6. 10.1016/S0022-5347(05)65072-0.CrossRefPubMed
29.
go back to reference Yoder BJ, Skacel M, Hedgepeth R, et al: Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. American journal of clinical pathology. 2007, 127 (2): 295-301. 10.1309/ADJL7E810U1H42BJ.CrossRefPubMed Yoder BJ, Skacel M, Hedgepeth R, et al: Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. American journal of clinical pathology. 2007, 127 (2): 295-301. 10.1309/ADJL7E810U1H42BJ.CrossRefPubMed
30.
go back to reference Lokeshwar VB, Habuchi T, Grossman HB, et al: Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology. 2005, 66 (6 Suppl 1): 35-63.CrossRefPubMed Lokeshwar VB, Habuchi T, Grossman HB, et al: Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology. 2005, 66 (6 Suppl 1): 35-63.CrossRefPubMed
Metadata
Title
ROS generation via NOX4 and its utility in the cytological diagnosis of urothelial carcinoma of the urinary bladder
Authors
Keiji Shimada
Tomomi Fujii
Satoshi Anai
Kiyohide Fujimoto
Noboru Konishi
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2011
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/1471-2490-11-22

Other articles of this Issue 1/2011

BMC Urology 1/2011 Go to the issue